Patents Assigned to Talecris Biotherapeutics, Inc.
-
Patent number: 8232369Abstract: The present invention relates to a method for precipitation of peptide where the mixing step of the peptide with the precipitation aid and the precipitation itself are specially separated.Type: GrantFiled: November 27, 2007Date of Patent: July 31, 2012Assignees: Talecris Biotherapeutics, Inc., Bayer Technology Services GmbHInventors: Hans-Jürgen Henzler, Stephan Kirchner, Dirk Havekost, Klaus Kaiser, Jörg Kauling, Richard Pasquinelli, Rolf Treckmann
-
Publication number: 20120009650Abstract: Compositions and methods for preparing plasminogen, in particular recombinant plasminogen, and compositions and methods of utilizing same for preparing plasmin are provided.Type: ApplicationFiled: March 2, 2010Publication date: January 12, 2012Applicant: Talecris Biotherapeutics, Inc.Inventors: Edward Koepf, Myies Lindsay, Rebecca Silverstein, Jennifer Hunt, James Rebbeor, Thomas Zimmerman, Charles Miller, Anthony Caronna, Kenya Stokes
-
Publication number: 20110318770Abstract: Compositions, kits, and methods for determining plasmin activity using a fluorogenic peptide substrate are provided.Type: ApplicationFiled: February 5, 2010Publication date: December 29, 2011Applicant: Talecris Biotherapeutics, Inc.Inventors: Kevin Yarbrough, Maria Cruz, Pete Vandeberg
-
Publication number: 20110237781Abstract: Purification of ?-1 proteinase inhibitor (?-1 PI) from solutions comprising ?-1 PI is accomplished using hydrophobic interaction chromatography (HIC). In some embodiments, purification of ?-1 PI is accomplished by precipitation of contaminating proteins from a starting solution comprising ?-1 PI, such as human plasma, followed by anion exchange resin chromatography prior to HIC. Further purification may be accomplished by an optional cation exchange chromatography subsequent to anion exchange chromatography but prior to HIC. Some embodiments of the invention also include virus removal and/or inactivation by methods such as nano filtration and such as contact with a non-ionic detergent. The methods of the present invention result in greater yield, purity, and pathogenic clearance of plasma fractions than known methods.Type: ApplicationFiled: July 17, 2009Publication date: September 29, 2011Applicant: Talecris Biotherapeutics, Inc.Inventors: Wytold Lebing, Scott A. Cook, Christopher A. Dadd
-
Publication number: 20110213126Abstract: The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a (two-stage ultrafiltration/diafiltration approach.Type: ApplicationFiled: April 14, 2009Publication date: September 1, 2011Applicant: Talecris Biotherapeutics, Inc.Inventors: Martin Gonzalez, Woody D. Wood, Fred H. Earp
-
Patent number: 7871608Abstract: A method of treating a subject, the method including administring a composition that includes a reversibly inactivated acidfied plasmin substantially free of a plasminogen activator, in a low buffering capacity buffer, wherein the composition is a solution suitable for pharmacenutical use that can be raised to physiological pH by adding no more than about 5 volumes of serum to the solution relative to a volume of the solution.Type: GrantFiled: August 25, 2008Date of Patent: January 18, 2011Assignee: Talecris Biotherapeutics, Inc.Inventors: Thomas P. Zimmerman, Valery Novokhatny, Shan Jiang, James Colandene
-
Publication number: 20110003332Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: ApplicationFiled: November 25, 2008Publication date: January 6, 2011Applicant: Talecris Biotherapeutics, Inc.Inventor: Valery Novokhatny
-
Publication number: 20110004411Abstract: Methods of managing results of a real-time polymerase chain reaction (PCR) instrument and software associated with such methods are described herein. One disclosed method, among others, comprises calculating, from results of the real-time PCR instrument, a fluorescence signal of a sample during a cycle of a baseline period of the real-time PCR instrument. The method further comprises determining whether or not the fluorescence signal during the baseline period increases by at least a certain percentage compared to cycles outside the baseline period. The sample is flagged as a potentially high-titer sample when the fluorescence signal increases by at least the certain percentage.Type: ApplicationFiled: November 11, 2008Publication date: January 6, 2011Applicant: Talecris Biotherapeutics, Inc.Inventors: Justin M. Paul, Burton D. Beames
-
Publication number: 20100304465Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: ApplicationFiled: April 21, 2005Publication date: December 2, 2010Applicant: Talecris Biotherapeutics, Inc.Inventors: Jennifer A. Hunt, Valery Novokhatny
-
Publication number: 20100196875Abstract: Nucleic acid molecules derived from sequences of novel human parvovirus B19 variant genomes are provided. Also provided are assays and kits comprising the nucleic acid molecules.Type: ApplicationFiled: January 15, 2008Publication date: August 5, 2010Applicant: Talecris Biotherapeutics, Inc.Inventors: Douglas C. Lee, Todd M. Gieman, Chris Glenn, Burton Beams, Brett Buno, Lori Rinckel
-
Publication number: 20100104551Abstract: A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ?-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ?-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), ?-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-?-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives.Type: ApplicationFiled: October 22, 2009Publication date: April 29, 2010Applicant: Talecris Biotherapeutics, Inc.Inventors: Dharmendra M. Jani, Kai Kwok, Gregory L. McIntire, Bruce A. Pfeffer, Afshin Shafiee, Ruiwen Shi, Srini Venkatesh, Hongna Wang, Yan Huang, Stephen R. Davio
-
Publication number: 20100093982Abstract: The present invention relates to a method for precipitation of peptide where the mixing step of the peptide with the precipitation aid and the precipitation itself are specially separated.Type: ApplicationFiled: November 27, 2007Publication date: April 15, 2010Applicant: TALECRIS BIOTHERAPEUTICS, INC.Inventors: Hans-Jurgen Henzler, Stephan Kirchner, Dirk Havekost, Klaus Kaiser, Jörg Kauling, Richard Pasquinelli, Rolf Treckmann
-
Publication number: 20090269359Abstract: The invention relates to a method of treating or preventing disease associated with ?-amyloid polypeptides comprising administration of an immunoglobulin preparation enriched in immunoglobulin M (IgM), and pharmaceutical compositions comprising such preparations.Type: ApplicationFiled: January 30, 2007Publication date: October 29, 2009Applicant: Talecris Biotherapeutics, Inc.Inventors: Philip Scuderi, JR., Afshin Safavi, Matthew G. Langevin
-
Publication number: 20090232798Abstract: A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.Type: ApplicationFiled: March 19, 2009Publication date: September 17, 2009Applicant: Talecris Biotherapeutics, Inc.Inventors: Ulrich Betz, Klaus-Peter Radtke
-
Patent number: 7544500Abstract: Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.Type: GrantFiled: October 23, 2003Date of Patent: June 9, 2009Assignee: Talecris Biotherapeutics, Inc.Inventors: Rita T. Bradley, Scott A. Cook, Christopher A. Dadd, Jonathan D. Kent, Marina N. Korneyeva, Valery V. Novokhatny, James F. Rebbeor, Christopher J. Stenland, Jonathan S. Strauss, Jarrett C. Terry, Jeffrey A. Yuziuk
-
Patent number: 6984492Abstract: A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.Type: GrantFiled: September 5, 2003Date of Patent: January 10, 2006Assignee: Talecris Biotherapeutics, Inc.Inventors: Ulrich Betz, Klaus-Peter Radtke
-
Patent number: 6969515Abstract: Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus. The method is applicable to the dissolution of thrombi in artificial devices, e.g., hemodialysis grafts.Type: GrantFiled: October 25, 2002Date of Patent: November 29, 2005Assignee: Talecris Biotherapeutics, Inc.Inventors: Gary J. Jesmok, Kyle A. Landskroner
-
Patent number: 6964764Abstract: Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.Type: GrantFiled: May 10, 2002Date of Patent: November 15, 2005Assignee: Talecris Biotherapeutics, Inc.Inventors: Thomas P. Zimmerman, Valery Novokhatny, Kyle A. Landskroner, Gary J. Jesmok, Kathryn K. Taylor